Minoxidil
Hair loss medicine: a solution or foam for the scalp is sold without a prescription, the tablet only on prescription.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is Minoxidil?
Minoxidil is an active ingredient used against hair loss: as a solution or foam applied to the scalp it is sold without a prescription, and as a tablet it needs one. It was originally developed as a tablet for high blood pressure, but because of the increased hair growth seen as a side effect it was also tried against hair loss.
It works by widening blood vessels, so the hair follicles receive more blood. It is estimated that about 40–50% of users get no effect. The form applied to the scalp is barely absorbed, whereas the tablet acts on the whole body. The tablet can cause fluid retention, a fast heartbeat and a drop in blood pressure. Its official prescribing information carries a boxed (black-box) warning: fluid can collect around the heart, which rarely leads to dangerous pressure on the heart. For this reason the tablet can only be used under close medical supervision. On the scalp it can cause itching, flaking and dryness, and solution running down the face can cause unwanted facial hair growth. It is not recommended in pregnancy or breastfeeding, because it passes into breast milk.
ATC code
D11AX01 (topical); oral C02DC01
Prescription
Over-the-counter (OTC) topical; oral prescription only (Rx)
Mechanism
ATP-sensitive K-channel opener (vasodilator); activated by SULT1A1
Half-life
22 h (topical); 3-4 h (oral)
Onset
2-4 months (visible hair regrowth)
No anecdote collected yet.
Data console
Lab data
Perera E, Sinclair R. . Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Research. 2017;6:1650..
Suchonwanit P, Thammarucha S, Leerunyakul K. . Topical minoxidil for androgenetic alopecia: meta-analysis. Drug Des Devel Ther. 2019;13:2777-2786..
Pirmez R, Salas-Callo CI. . Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2020;82(1):e21-e22..
Olsen EA, Dunlap FE, Funicella T, et al. . A double-blind, randomized clinical trial of 5% minoxidil vs 2% in men. J Am Acad Dermatol. 2002;47(3):377-385..
Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. . Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651..
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Fluid retention and edema (oral): sodium and water retention, ankle and facial swelling, weight gain; often requires a co-administered diuretic (e.g. furosemide).
- Reflex tachycardia and palpitations: vasodilation triggers a compensatory rise in heart rate (+10–20 bpm), which can worsen angina with the oral form.
- Hypotension and postural hypotension (oral): systemic blood-pressure drop, dizziness, light-headedness; additive effect with antihypertensives.
- Hypertrichosis and hirsutism: unwanted body and facial hair growth, more pronounced with systemic (oral) exposure; the most common reason women discontinue treatment.
- Initial paradoxical shedding (telogen effluvium): a transient increase in hair loss in the first 2–8 weeks before regrowth begins, not a treatment failure.
- Local scalp reactions (topical): itching, flaking, dryness, redness; often propylene-glycol-vehicle contact dermatitis (the foam formulation is PG-free).
- Unwanted facial hair from runoff (topical): solution reaching the forehead, temples or ears can cause local hair growth if it is not allowed to dry properly.
Contraindications · 2
- Active scalp dermatitis or infection
- Contact allergy to propylene glycol (foam formulation is PG-free alternative)
Related Hair & Skin
Same therapeutic category
Studies
Related research and clinical findings
Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study
Perera E, Sinclair R.
Topical minoxidil for androgenetic alopecia: meta-analysis
Suchonwanit P, Thammarucha S, Leerunyakul K.
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation
Pirmez R, Salas-Callo CI.
A double-blind, randomized clinical trial of 5% minoxidil vs 2% in men
Olsen EA, Dunlap FE, Funicella T, et al.
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al.
Telegram
Have a question about Minoxidil?
Educational hair and skin info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation. Talk to a dermatologist!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.

